Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Parkinson Disease: HELP
Olivier Rascol
Based on 106 articles published since 2007
||||
Expertise Level
The expertise of Olivier Rascol ranks in the
  • Top 0.029%
  • ... of 65,797 published authors worldwide on Parkinson Disease
  • ... from 2007 through 2018
  • ... based on contributions to 106 articles on the topic.
Graphical view (beta)
Uncounted papers?
Get your prestigious
World Expert badge
similar to this:
 
Work Locations
Details
Most likely:    Universite de Toulouse      
2017
  • From the Institute of Neurology (F.S.), IRCCS San Raffaele, Rome, Italy; Departments of Clinical Pharmacology and Neurosciences (O.R.), Clinical Investigation Center CIC1436, NS-Park Clinical Research Network, NeuroToul Centre of Excellence in Neurodegeneration, INSERM, Toulouse University Hospital and Toulouse University, France; Parkinson's Disease and Movement Disorders Center (R.A.H.), USF Health-Byrd Institute, Tampa, FL; and Merck & Co., Inc. (S.H., A.T., R.C., T.W.H., P.S., C.L., D.M., D.J.H.), Kenilworth, NJ. · From the Institute of Neurology (F.S.), IRCCS San Raffaele, Rome, Italy; Departments of Clinical Pharmacology and Neurosciences (O.R.), Clinical Investigation Center CIC1436, NS-Park Clinical Research Network, NeuroToul Centre of Excellence in Neurodegeneration, INSERM, Toulouse University Hospital and Toulouse University, France; Parkinson's Disease and Movement Disorders Center (R.A.H.), USF Health-Byrd Institute, Tampa, FL; and Merck & Co., Inc. (S.H., A.T., R.C., T.W.H., P.S., C.L., D.M., D.J.H.), Kenilworth, NJ. · Pubmed 28490648
  • Reta Lila Weston Institute, University College London, London, England. · Centro de Estudos Egas Moniz, Hospital de Santa Maria, Lisbon, Portugal. · Department of Clinical Pharmacology, Institut National de la Santé et de la Recherche Medicale (INSERM) and University Hospital of Toulouse, Toulouse, France4Department of Neurosciences, INSERM and University Hospital of Toulouse, Toulouse, France. · Department of Neurology, Innsbruck Medical University, Innsbruck, Austria. · Department of Research and Development, BIAL-Portela & Ca SA, Sao Mamede do Coronado, Portugal. · Quintiles, Dublin, Ireland. · Department of Research and Development, BIAL-Portela & Ca SA, Sao Mamede do Coronado, Portugal8Department of Pharmacology and Therapeutics, University Porto, Porto, Portugal. · Pubmed 28027332
  • Laboratoire de Pharmacologie Médicale et Clinique, UMR Inserm 1027, CHU de Toulouse, France. · Pôle Pharmacie, UMR Inserm 1027, CHU de Toulouse, France. · Service de Gériatrie, CHU de Toulouse, UMR Inserm 1027, France. · Laboratoire de Pharmacologie Médicale et Clinique, CIC 1436, CHU de Toulouse, Inserm 1027, France. · Laboratoire de Pharmacologie Médicale et Clinique, CIC 1436, CHU de Toulouse, Inserm 1027, France. Electronic address: · Pubmed 28623157
  • Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · INSERM UMR 1027, Faculté de Médecine, Université de Toulouse, Toulouse, France. · CIC INSERM 1436, Université et Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire deToulouse, Toulouse, France. · INSERM UMR 825, Université de Toulouse, Toulouse, France. · Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · INSERM UMR 1027, Faculté de Médecine, Université de Toulouse, Toulouse, France. · CIC INSERM 1436, Université et Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire deToulouse, Toulouse, France. · Pubmed 27796464
2016
  • Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Rehabilitation, Nijmegen, The Netherlands. · Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands. · Department of Clinical Pharmacology and Neurosciences, NeuroToul Center of Excellence in Neurodegeneration (COEN), University Hospital and University of Toulouse, Toulouse, France. · INSERM CIC1436, UMR1214, and NS-Park/FCRIN Clinical Research Network Toulouse, Toulouse, France. · Pubmed 27430479
  • Institute of Cardiology Research, University of Buenos Aires, National Research Council (CONICET-ININCA), Buenos Aires, Argentina. · Department of Clinical Pharmacology and Neurosciences and NeuroToul Center of Excellence in Neurodegeneration (COEN), University Hospital and University of Toulouse III, Toulouse, France. · INSERM CIC1436 and UMR1214, Toulouse, France. · NS-Park/FCRIN Network, INSERM, Toulouse, France. · Pubmed 27344665
  • Service de Pharmacologie Médicale et Clinique, Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse, Toulouse, France. · Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament et Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · INSERM UMR 1027, Faculté de Médecine, Université de Toulouse, Toulouse, France. · CIC INSERM 1436, Université et Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire, France. · INSERM UMR 825, Université de Toulouse, Toulouse, France. · Département de Pharmacologie, Université et Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. · INSERM U 657, Pharmacoepidemiology, Université et Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. · Pubmed 27028036
  • a Institute of Cardiologic Research, National Scientific and Research Council (ININCA-CONICET), Faculty of Medicine , University of Buenos Aires , Buenos Aires , Argentina. · b Department of Clinical Pharmacology and Neurosciences , NeuroToul Excellence Center for Neurodegenerative Disorders, University Hospital and University of Toulouse 3 , Toulouse , France. · c INSERM CIC1436 and UMR825 , Toulouse , France. · d NS-Park Network, INSERM , Toulouse , France. · Pubmed 26849427
  • Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France. · CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France. · Service de Neurologie, CHU de Bordeaux, Bordeaux, France. · NS-Park/FCRIN Network, UMS 015, Toulouse, France. · Addex Pharma SA, Plan Les Ouates, Switzerland. · NS-Park/FCRIN Network, UMS 015, Toulouse, France. · Neurology Service, A, Hôpital Gabriel Montpied, Clermont Ferrand, France. · Sorbonne Universités and UPMC Univ Paris 06, INSERM UMRS-1127 and CIC-1422; CNRS UMR-7225; AP-HP; and ICM, Hôpital Pitié-Salpêtrière, Paris, France. · Universitätsklinikum Giessen und Marburg, Klinik für Neurologie, Marburg, Germany. · Department of Neurology USC/Keck School of Medicine, Los Angeles, California, USA. · Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, USA. · Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France. · CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France. · Rush University Medical Center, Dept. of Neurological Sciences, Movement Disorder Section, Chicago, Illinois, USA. · Paracelsus Elena Klinik, centre for Parkinson's Disease & Movement Disorders, Kassel, Germany. · CIC9302, Departments of Clinical Pharmacology and Neurosciences and NeuroToul COEN Center; INSERM, University Hospital of Toulouse and University of Toulouse 3, Toulouse, France. · Pubmed 27214664
  • Paracelsus-Elena Hospital, Kassel, Germany. · Department of Neurosurgery, University Medical Center, Goettingen, Germany. · German Parkinson Study Group, Marburg, Germany. · Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, Tübingen, Germany. · Department of Clinical Pharmacology and Neurosciences, NeuroToul Excellence Center for Neurodegenerative Disorders, University UPS of Toulouse III, CIC-9302/INSERM UMR825, Hôpital Purpan - Pavillon Riser, Toulouse, France. · NS PARK/FCRIN Network, France. · Department of Neurology, Philipps-University of Marburg, Marburg, Germany. · Schön Klinik München-Schwabing, München, Germany. · Sorbonne Universités, UPMC Univ Paris 06, and INSERM UMRS 1127 /CIC-1422, and CNRS UMR 7225, and AP-HP, and ICM, Hôpital Pitié-Salpêtrière, Département des maladies du système nerveux, Paris, France. · Division of Neurodegenerative Diseases, Department of Neurology, Dresden University of Technology, Dresden, Germany. · Department of Neurology, UC Davis MIND Institute, Sacramento, California, USA. · Service de Neurologie et pathologie du Mouvement, Hôpital de la Timone, Marseille Cedex, France. · Univisité Lyon 1, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Lyon, France. · CNRS UMR 5229, Centre de Neurosciences Cognitives, Team Basal Ganglia, Bron, France. · Service de Neurologie et Pathologie du movement, EA 1046, CHU de Lille, Hôpital Roger Salengro, Lille, France. · Movement to Health (M2H) laboratory, Euromov, University Montpellier 1, Hôpital gui de Chauliac, Montpellier, France. · Center for Neurological Restoration, Cleveland Clinic, Cleveland, Ohio, USA. · Department of Neurology, Institute for Research and Medical Care, IROCS, Rome, Italy. · Service de Neurologie, Hôpital de Hautepierre, Strasbourg, France. · Centre Investigation Clinique Neurologie, CHU Nantes, Hôpital G&R Laennec, Nantes, France. · Service de Neurologie, Hôpital Gabriel Montpied, Clermont-Ferrand, France. · Department of Neurology, James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, University of Cincinnati Academic Health Center, Cincinnati, Ohio, USA. · Feinstein Institute for Medical Research, North Shore - LIJ Health System, Manhasset, New York, USA. · Service de Neurologie, CIC-INSERM 1402, CHU de Poitiers, Université de Poitiers, Poitiers, France. · Klinik Haag, Haag, Germany. · Neuroscience Research Unit, Centre de recherche du CHU de Québec, Québec, Canada. · Faculty of Pharmacy, Laval University, Québec, Canada. · Novartis Institutes for BioMedical Research, Basel, Switzerland. · Biometrics Matters Ltd, Hamilton, New Zealand. · Albert Einstein College of Medicine, New York, NY, USA, and CognitionMetrics, LLC, Wilmington, Delaware, USA. · Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. · Inbiomed, San Sebastian, Spain. · CogState, Inc, New Haven, Connecticut, USA. · Department of Neurology and Neurosurgery, McGill University, Montreal, Québec, Canada. · Pubmed 26990766
  • Departments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC-1436, NS-Park/FCRIN Network and NeuroToul COEN Center of Excellence in Neurodegeneration, INSERM, University Hospital of Toulouse, and University of Toulouse 3, Toulouse, France. · Parkinson's Disease and Movement Disorders Center, NPF Center of Excellence, Tampa, Florida, USA. · Department of Neurology, Institute for Research and Medical Care IRCCS San Raffaele, Rome, Italy. · CHDI Management/CHDI Foundation, Princeton, New Jersey, USA. · Teva Pharmaceuticals, Petah Tikva, Israel. · Teva Pharmaceuticals, Frazer, Pennsylvania, USA. · Departments of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA. · Pubmed 27431201
  • Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal. · University College London, Reta Lila Weston Institute, London, UK. · Department of Research and Development, BIAL-Portela and Ca SA, S Mamede do Coronado, Portugal. · Department of Neurology, Innsbruck Medical University, Innsbruck, Austria. · Department of Clinical Pharmacology, INSERM and University Hospital of Toulouse, Toulouse France; Department of Neurosciences, INSERM and University Hospital of Toulouse, Toulouse France. · Department of Research and Development, BIAL-Portela and Ca SA, S Mamede do Coronado, Portugal; Department of Pharmacology and Therapeutics, Faculty of Medicine, University Porto, Porto, Portugal; MedInUP, Center for Drug Discovery and Innovative Medicines, University Porto, Porto, Portugal. Electronic address: · Pubmed 26725544
  • INSERM, Imagerie Cérébrale et Handicaps Neurologiques, UMR 825, 31059, Toulouse, France. · Université de Toulouse (UPS), Imagerie Cérébrale et Handicaps Neurologiques, Toulouse, France. · Institute of Neurology, University Magna Graecia, Catanzaro, Italy. · Service of Neurology, University Hospital "Marqués de Valdecilla (IFIMAV)," University of Cantabria and "Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED),", Santander, Spain. · Neuroscience Department, Retzius vag 8, Karolinska Institutet, Stockholm, Sweden. · Centre de Référence Atrophie Multisystématisée, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · Centre de Référence Atrophie Multisystématisée, Centre Hospitalier Universitaire de Bordeaux, Pessac, France. · Service de Neurologie, Centre Hospitalier Universitaire de Bordeaux, Pessac, France. · Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France. · CNRS, Institut des Maladies Neurodégénératives, Bordeaux, France. · Département de Pharmacologie Clinique, INSERM CIC1436, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · Pubmed 26676922
  • Clinical Investigation Center CIC1436 and Department of Clinical Pharmacology and Neurosciences, INSERM, Toulouse University Hospital and University of Toulouse, Toulouse, France. · University of South Florida Ataxia Research Center, The Frances J. Zesiewicz Foundation for Parkinson's Disease at USF, Parkinson's Disease and Movement Disorders Clinic at the PADREC, James A. Haley Veterans' Administration, Tampa, FL, USA. · National Parkinson's Foundation International Centre of Excellence, King's College Hospital, Kings College and Kings Health Partners, London, UK. · UCB Pharma, Raleigh, NC, USA. · UCB Pharma, Monheim am Rhein, Germany. · UCB Pharma, Brussels, Belgium. · Pubmed 26626320
2015
  • Department of Clinical Pharmacology and Neurosciences, University Hospital and University of Toulouse 3, France. · INSERM CIC1436 and UMR825, Toulouse, France. · Laboratory of Epidemiology and Experimental Pharmacology, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA). · National Scientific and Technological Research Council (CONICET), Buenos Aires, Argentina. · Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal. · Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal. · Pubmed 26293004
  • Parkinson's Disease and Movement Disorders Center, University of South Florida, National Parkinson Foundation Center of Excellence, Tampa. · Institute of Neurology, L'Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele, Rome, Italy. · Clinical Investigation Center, Institut National de la Santé et de la Récherche Médicale, Toulouse University, Toulouse, France. · Merck & Co, Inc, Kenilworth, New Jersey. · Pubmed 26523919
  • Paracelsus-Elena Hospital, Kassel, Germany; Department of Neurosurgery, University Medical Centre, Goettingen, Germany. Electronic address: · National Parkinson's Foundation, Parkinson's Centre of Excellence, King's College Hospital, London, UK; Biomedical Research Unit for Dementia, King's College, London, UK. · National Centre of Epidemiology, Carlos III Institute of Health, Madrid, Spain. · Clinical Investigation Centre 1436, INSERM, Toulouse, France; University Hospital, Toulouse, France. · Neurologie Berlin, Gemeinschaftspraxis, Berlin, Germany. · Poliklinika Chocen Neuro, Chocen, Czech Republic; Department of Neurology, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Hradec Králové, Czech Republic. · Department of Neurology, Vaszary Kolos Hospital, Esztergom, Hungary. · Department of Neurology, Jagiellonian University, Krakow, Poland. · Parkinson's Disease and Movement Disorders Unit, Department of Neurology, Hospital Clinic, CIBERNED, Barcelona, Spain. · Mundipharma Research, Limburg an der Lahn, Germany; Private University Witten/Herdecke, Faculty of Health, Witten, Germany. · Mundipharma Research, Limburg an der Lahn, Germany; Rudolf-Buchheim Institute of Pharmacology, Justus-Liebig-Universität Giessen, Germany. · Mundipharma Research, Cambridge, UK. · Mundipharma Research, Limburg an der Lahn, Germany. · Pubmed 26494524
  • Wolfson Centre for Age-Related Diseases, King's College London, London, UK. Electronic address: · Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL. · ACADIA Pharmaceuticals, San Diego, CA. · Wolfson Centre for Age-Related Diseases, King's College London, London, UK. · University of Kansas Medical Center, Kansas City, KS. · Department of Clinical Pharmacology and Neurosciences, University UPS of Toulouse III, Toulouse, France. · Institute of Neuroscience, Newcastle University, Newcastle, UK. · Pubmed 26239690
  • Department of Clinical Pharmacology, Paul Sabatier University and Toulouse University Hospital, Toulouse, France; INSERM UMR825 Neuroimaging and Neurologic Diseases, Toulouse, France; Sleep and Epilepsy Center, Neurocenter of Southern Switzerland, Civic Hospital (EOC) of Lugano, Switzerland. Electronic address: · Department of Clinical Pharmacology, Paul Sabatier University and Toulouse University Hospital, Toulouse, France; LN-Pharma, Toulouse, France. · Department of Clinical Pharmacology, Paul Sabatier University and Toulouse University Hospital, Toulouse, France. · Sleep Medicine and Epilepsy Unit, IRCCS "C. Mondino National Institute of Neurology" Foundation, Pavia, Italy. · Pôle Neurosciences, Centre Hospitalier Universitaire de Nantes, Centre d'Investigation Clinique CIC 04, Nantes, France. · Service de Neurologie, Groupe Hospitalier Sud, Hôpital Haut-Lévèque, Centre Hospitalier Universitaire de Bordeaux, France. · Service de Neurologie et pathologie du mouvement, Pôle de Neurologie, Centre Hospitalier Universitaire de Lille, France. · Department of Clinical Pharmacology, Paul Sabatier University and Toulouse University Hospital, Toulouse, France; INSERM UMR825 Neuroimaging and Neurologic Diseases, Toulouse, France; Centre d'Investigation Clinique CIC 9302, Toulouse University Hospital, Toulouse, France. · Pubmed 26411501
  • Department of Clinical Pharmacology and Neurosciences, University of Toulouse 3, 37 Allées Jules Guesde, 31000, Toulouse, France. · INSERM CIC1436 and UMR825, Toulouse, France. · NS-Park Network, INSERM, Toulouse, France. · Department of Clinical Pharmacology and Neurosciences, University of Toulouse 3, 37 Allées Jules Guesde, 31000, Toulouse, France. · Laboratory of Epidemiology and Experimental Pharmacology, Institute for Biomedical Research (BIOMED-CONICET), Faculty of Medical Sciences, Pontifical Catholic University of Argentina (UCA), Buenos Aires, Argentina. · NS-Park Network, INSERM, Toulouse, France. · Department of Neurology, Hôpital Laënnec, CHU Nantes, Nantes, France. · Department of Neurology, CHU Lille, Lille, France. · Department of Neurology, Hôpital Laënnec, CHU Nantes, Nantes, France. · NS-Park Network, INSERM, Toulouse, France. · Department of Neurology, CHU Lille, Lille, France. · INSERM U 837 Eq6, Lille, France. · Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, Bordeaux, France. · Institut des Maladies Neurodégénératives, UMR 5293, CNRS, Bordeaux, France. · Service de Neurologie, CHU de Bordeaux, Bordeaux, France. · NS-Park Network, INSERM, Toulouse, France. · Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, Bordeaux, France. · Institut des Maladies Neurodégénératives, UMR 5293, CNRS, Bordeaux, France. · Service de Neurologie, CHU de Bordeaux, Bordeaux, France. · NS-Park Network, INSERM, Toulouse, France. · LN Pharma, Toulouse, France. · Pubmed 25845678
  • 1 Department of Movement Disorders and Neurology, Lille University, CHU Lille, Lille, France 2 INSERM U1171, Lille University, Lille, France. · 3 Department of Molecular Biology and Pathology Centre, Lille University, CHU Lille, Lille, France. · 4 Sorbonne Universités, UPMC Univ Paris 06, and INSERM UMRS_1127 and CIC_1422, and CNRS UMR_7225, and AP-HP, and ICM, Hôpital Pitié-Salpêtrière, Département des Maladies du Système Nerveux, Paris, France. · 5 Department of Biostatistics, Lille University, CHU Lille, Lille, France. · 2 INSERM U1171, Lille University, Lille, France. · 6 Department of Nuclear Medicine, Lille University, CHU Lille, Lille, France. · 7 Departments of Clinical Pharmacology and Neurosciences, CIC9302, University Hospital and Paul Sabatier University, Toulouse, France. · 8 Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR CNRS 5293 and CHU de Bordeaux, Bordeaux, France. · 9 Department of Neurology and Movement Disorders - APHM Timone University Hospital and Institut de Neurosciences de la Timone, AMU-CNRS UMR 7289, Marseille, France. · 10 Department of Psychiatry and Neurology, CHU Grenoble, Grenoble, France. · 11 Department of Movement Disorders and Neurology, Centre d'Investigation Clinique, INSERM CIC 0802, INSERM U1084, Laboratoire de Neurosciences Expérimentales et Cliniques, CHU de Poitiers, Poitiers, France. · 12 Department of Movement Disorders and Neurology, CHU Strasbourg, Strasbourg, France. · 13 Department of Movement Disorders and Neurology, CHU Clermont-Ferrand, Clermont-Ferrand, France. · 14 Department of Movement Disorders and Neurology, INSERM, CIC04, CHU Nantes, Nantes, France. · 15 Department of Movement Disorders and Neurology, CHU Nice, Nice, France. · 16 Department of Neurology, EA- 425 Université Rennes 1 et CHU Pontchaillou, CHU Rennes, Rennes, France. · 17 Department of Neurology and INSERM CIC-CRB 0204, Rouen University Hospital, CHU Rouen Rouen, France. · 1 Department of Movement Disorders and Neurology, Lille University, CHU Lille, Lille, France 18 INSERM U837/6 Lille JPARC, France. · 7 Departments of Clinical Pharmacology and Neurosciences, CIC9302, University Hospital and Paul Sabatier University, Toulouse, France 19 INSERM NS-PARK National Network, France. · 2 INSERM U1171, Lille University, Lille, France 18 INSERM U837/6 Lille JPARC, France. · 1 Department of Movement Disorders and Neurology, Lille University, CHU Lille, Lille, France 2 INSERM U1171, Lille University, Lille, France 20 Department of Medical Pharmacology, Lille University, CHU Lille, Lille, France · Pubmed 25805645
  • Department of Clinical Pharmacology, Toulouse University Hospital and Paul Sabatier University, Toulouse, France; UMR 825 Brain imaging and neurological dysfunctions, INSERM, Toulouse, France; Sleep and Epilepsy center, Neurocenter of Southern Switzerland, Civic Hospital (EOC) of Lugano, Lugano, Switzerland. · Department of Neurology, Toulouse University Hospital and Paul Sabatier University, Toulouse, France. · Sleep Medicine and Epilepsy unit, C. Mondino National Neurological Institute, Pavia, Italy. · UMR 825 Brain imaging and neurological dysfunctions, INSERM, Toulouse, France; Department of Neurology, Toulouse University Hospital and Paul Sabatier University, Toulouse, France. · Brain Function & Neuromodulation, Grenoble Institute of Neuroscience, Grenoble, France; Joseph Fourier University, Grenoble, France. · Brain Function & Neuromodulation, Grenoble Institute of Neuroscience, Grenoble, France. · Department of Clinical Pharmacology, Toulouse University Hospital and Paul Sabatier University, Toulouse, France; UMR 825 Brain imaging and neurological dysfunctions, INSERM, Toulouse, France; Reference Centre for Multiple System Atrophy, Toulouse University Hospital, Toulouse, France. · Pubmed 25756280
  • INSERM, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU PURPAN, Toulouse, France; Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU PURPAN, Toulouse, France. Electronic address: · Radiology Department, Santa Lucia Foundation, Rome, Italy. · INSERM, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU PURPAN, Toulouse, France; Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU PURPAN, Toulouse, France; Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, CHU PURPAN, Toulouse, France; Service de Pharmacologie Clinique, Faculté de Médecine, Toulouse, France; Inserm, Centre d'Investigation Clinique 9302, CHU Purpan, Toulouse, France. · INSERM, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU PURPAN, Toulouse, France; Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU PURPAN, Toulouse, France. · Pubmed 25174648
2014
  • Clinical Investigation Center CIC9302 and Department of Neurosciences and Clinical Pharmacology, INSERM UMR825, Toulouse University Hospital and University of Toulouse III, Toulouse, France. · Movement Disorder Clinic, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada. · Novartis Institutes for Biomedical Research, Basel, Switzerland. · Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. · Neuroscience Research Unit, Centre Hospitalier Universitaire de Québec, Québec, Canada; Faculty of Pharmacy, Laval University, Québec, Canada. · Novartis Institutes for Biomedical Research, Basel, Switzerland; Department of Neurology and Neurosurgery, McGill University, Montreal, Québec, Canada. Electronic address: · Pubmed 24951359
  • Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France. · CHU de Bordeaux, Unité de Soutien Méthodologique à la Recherche Clinique (USMR), Pôle de santé publique, Bordeaux, France. · Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France; Service de Neurologie, CHU de Bordeaux, F-33604 Pessac, France. · Centre de référence atrophie multisystématisée, CHU de Toulouse, Toulouse, France. · Centre de référence atrophie multisystématisée, CHU de Toulouse, Toulouse, France; Department of Clinical Pharmacology, University Hospital and University of Toulouse 3, Toulouse, France; Department of Neurosciences, University Hospital and University of Toulouse 3, Toulouse, France; INSERM UMR825 and CIC9302, Toulouse, France. · Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France; Service de Neurologie, CHU de Bordeaux, F-33604 Pessac, France; Centre de référence atrophie multisystématisée, CHU de Bordeaux, Pessac, France. · Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France; Service de Neurologie, CHU de Bordeaux, F-33604 Pessac, France; Centre de référence atrophie multisystématisée, CHU de Bordeaux, Pessac, France. Electronic address: · Pubmed 24727096
  • AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesthésie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Créteil, France; Université Paris 12, Faculté de Médecine, Créteil, France. Electronic address: · AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesthésie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Créteil, France; Université Paris 12, Faculté de Médecine, Créteil, France. · Oxford BioMedica, Oxford, UK. · CEA, DSV I(2)BM, MIRCen and CNRS URA2210, Fontenay-aux-Roses, France. · John van Geest Centre for Brain Repair and Addenbrooke's Hospital, Cambridge, UK. · AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesthésie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Créteil, France; Université Paris 12, Faculté de Médecine, Créteil, France; INSERM U955, E01, Institut de Recherche Biomédicale, Créteil, France. · Gene Therapy, Centre of Neuroinflammation and Neurodegeneration, Division of Brain Sciences, Faculty of Medicine, Hammersmith Hospital Campus, London, UK. · CIC9302 and UMR 825, INSERM and Department of Pharmacology and Neurosciences, University Hospital and University of Toulouse III, Toulouse, France. · AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesthésie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Créteil, France; Université Paris 12, Faculté de Médecine, Créteil, France; CEA, DSV I(2)BM, MIRCen and CNRS URA2210, Fontenay-aux-Roses, France. · Pubmed 24412048
  • Clinical Investigation Centre CIC1436, Departments of Clinical Pharmacology and Neurosciences, INSERM and Toulouse University Hospital, University of Toulouse 3, Place du Docteur Baylac, TSA 40031, 31059 Toulouse CEDEX 9, France. · Pubmed 25134709
  • Department of Clinical Pharmacology, Faculty of Medicine, University Hospital, University of Toulouse, Toulouse, France2Department of Neurosciences, University Hospital, University of Toulouse, Toulouse, France3Clinical Investigation Center 1436, Universi. · LN Pharma, Toulouse, France. · Department of Neurology, Hôpital Laënnec, Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France6NS-Park Network, INSERM, Toulouse, France. · Department of Neurology, CHU Lille, Lille, France. · NS-Park Network, INSERM, Toulouse, France7Department of Neurology, CHU Lille, Lille, France8INSERM U 837 Eq6, Lille, France. · Institut des Maladies Neurodégénératives, Université de Bordeaux, Bordeaux, France10Centre National de la Recherche Scientifique, Institut des Maladies Neurodégénératives, Bordeaux, France11Service de Neurologie, CHU de Bordeaux, Bordeaux, France. · Neurology Department, Kantonsspital Münsterlingen, Münsterlingen, Switzerland. · NS-Park Network, INSERM, Toulouse, France9Institut des Maladies Neurodégénératives, Université de Bordeaux, Bordeaux, France10Centre National de la Recherche Scientifique, Institut des Maladies Neurodégénératives, Bordeaux, France11Service de Neurologie. · Pubmed 24839938
  • Clinical Investigation Center CIC-9302, NS-Park Network and Departments of Clinical Pharmacology and Neurosciences, INSERM, Toulouse University Hospital and University Paul Sabatier Toulouse III, Toulouse, France. Electronic address: · Pubmed 24361113
2013
  • CIC-9302/INSERM UMR825, Departments of Clinical Pharmacology and Neurosciences, University UPS of Toulouse III, Toulouse, France. · Pubmed 23485609
2012
  • Institut National de la Santé et de la Recherche Médicale Clinical Investigation Center, Toulouse University Hospital and University of Toulouse, France. · Pubmed 22222634
  • Department of Clinical Pharmacology, Hospital and University Paul Sabatier of Toulouse, France. · Pubmed 21585523
2011
  • Department of Clinical Pharmacology, University Hospital of Toulouse, France. · Pubmed 21626552
2010
  • Departments of Clinical Pharmacology and Neurosciences, Toulouse University Hospital, INSERM CIC9302-UMR825 Toulouse, France. · Pubmed 20669265
  • Department of Clinical Pharmacology, INSERM Clinical Investigation Center CIC-9302 and UMR-825, CHU Toulouse-Purpan and University Paul Sabatier, Toulouse, France. · Pubmed 20063435
2009
  • Clinical Investigation Center, Department of Neurosciences, University Hospital of Toulouse, INSERM UMR 825, Toulouse, France. · Pubmed 19221315
2008
  • Laboratoire de Pharmacologie Médicale et Clinique, Pôle Neurosciences, Centre d'Investigations Cliniques, Institut National de la Santé et de la Récherche Médicale, Unité 825, University Hospital, Toulouse, France. · Pubmed 18474731
2014
  • Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences , Toulouse , France. · Pubmed 24547918
  • Departments of Clinical Pharmacology and Neurosciences, Faculty of Medicine, University Hospital and University of Toulouse 3, 37 Allées Jules Guesde, 31000, Toulouse, France, · Pubmed 24683045
  • From INSERM, Clinical Investigation Center 9302 (F.O.-M., C.B.-C., E.D., M.G., C.T., A.S., O.R.), and Department of Neurology (F.O.-M., C.B.-C., O.R.), University Hospital of Toulouse; INSERM, Clinical Investigation Center 9503 (J.-C.C., A.-M.B., M.V.), and AP-HP, Department of Neurology (J.-C.C., A.-M.B., M.V.), Pitié-Salpêtrière Hospital, Paris; CRICM UPMC/INSERM UMR_S975 CNRS UMR7225 (J.-C.C., M.V.), Institut de la Moelle et du Cerveau, Université Pierre Marie Curie Paris-6, Salpêtrière, Paris; AP-HM (J.-P.A.), Department of Neurology, Timone Hospital, Marseille; Department of Clinical Pharmacology (C.B.-C., C.T., A.S., O.R.), University of Medicine, Toulouse; INSERM (C.B.-C., O.R.), and Université de Toulouse, UPS (C.B.-C., O.R.), Imagerie cérébrale et handicaps neurologiques, UMR 825, Toulouse; Department of Neurology (P.D., T.L.), University Hospital of Nantes; Department of Neurology (A.D.), University Hospital of Lille; Department of Neurology (F.D.), University Hospital of Clermont-Ferrand; Department of Neurology (W.M., F.T.), University Hospital of Bordeaux; and Department of Neurology (F.V.), Pays-d'Aix Hospital, Aix-en-Provence, France. · Pubmed 24371304
2013
  • University of Toulouse III, University Hospital, Department of Clinical Pharmacology and Neuroscience, Toulouse, France. · Pubmed 23373820
  • Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse, Toulouse, France. · Pubmed 22320451
  • Inserm, Imagerie cérébrale et handicaps neurologiques, UMR 825, F-31059 Toulouse, France - Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, F-31059 Toulouse, France. · Pubmed 23462484
2012
  • University Hospital and University Paul Sabatier Toulouse 3, Departments of Clinical Pharmacology and Neurosciences, France. · Pubmed 22530847
  • Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, l'Université de Toulouse, Toulouse, France. · Pubmed 22336566
  • Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine, Université de Toulouse, Toulouse, France. · Pubmed 22205275
2011
  • Departments of Clinical Pharmacology and Neurosciences, University Hospital and University of Toulouse, France and INSERM CIC-9023 and UMR-825, Toulouse, France; Department of Clinical Pharmacology, Faculty of Medicine, 37 Allées Jules Guesde, 31000, Toulouse, France. · Pubmed 21721909
  • Reference Centre for MSA, University Hospital, INSERM U1048 Eq8, Toulouse, France. · Pubmed 21547951
2010
  • Department of Clinical Pharmacology and Neurosciences, Hospital and University of Toulouse and INSERM CIC9023 and UMR 825, Toulouse, France. · Pubmed 20932066
  • Department of Clinical Pharmacology, University of Toulouse, Faculty of Medicine, 37 Allées Jules Guesde, 31000 Toulouse, France. · Pubmed 20670197
  • Department of Neurosciences, University Hospital, Toulouse, France. · Pubmed 20803301
2009
2008
  • Department of Clinical Pharmacology, University Hospital, Toulouse, France. · Pubmed 18546344
2007
  • Department of Neurology, University Hospital CHU, Toulouse, France. · Pubmed 17516457
Probable:    IRCCS San Raffaele Pisana      
2017
  • From the Institute of Neurology (F.S.), IRCCS San Raffaele, Rome, Italy; Departments of Clinical Pharmacology and Neurosciences (O.R.), Clinical Investigation Center CIC1436, NS-Park Clinical Research Network, NeuroToul Centre of Excellence in Neurodegeneration, INSERM, Toulouse University Hospital and Toulouse University, France; Parkinson's Disease and Movement Disorders Center (R.A.H.), USF Health-Byrd Institute, Tampa, FL; and Merck & Co., Inc. (S.H., A.T., R.C., T.W.H., P.S., C.L., D.M., D.J.H.), Kenilworth, NJ. · From the Institute of Neurology (F.S.), IRCCS San Raffaele, Rome, Italy; Departments of Clinical Pharmacology and Neurosciences (O.R.), Clinical Investigation Center CIC1436, NS-Park Clinical Research Network, NeuroToul Centre of Excellence in Neurodegeneration, INSERM, Toulouse University Hospital and Toulouse University, France; Parkinson's Disease and Movement Disorders Center (R.A.H.), USF Health-Byrd Institute, Tampa, FL; and Merck & Co., Inc. (S.H., A.T., R.C., T.W.H., P.S., C.L., D.M., D.J.H.), Kenilworth, NJ. · Pubmed 28490648
2013
  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy. · Pubmed 23853029
2010
  • Institute of Neurology, IRCCS San Raffaele Pisana, Rome, Italy. · Pubmed 20582993
Probable:    Miscellaneous institutions in Toulouse      
2017
  • Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · INSERM UMR 1027, Faculté de Médecine, Université de Toulouse, Toulouse, France. · CIC INSERM 1436, Université et Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire deToulouse, Toulouse, France. · INSERM UMR 825, Université de Toulouse, Toulouse, France. · Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · INSERM UMR 1027, Faculté de Médecine, Université de Toulouse, Toulouse, France. · CIC INSERM 1436, Université et Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire deToulouse, Toulouse, France. · Pubmed 27796464
2016
  • Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Rehabilitation, Nijmegen, The Netherlands. · Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands. · Department of Clinical Pharmacology and Neurosciences, NeuroToul Center of Excellence in Neurodegeneration (COEN), University Hospital and University of Toulouse, Toulouse, France. · INSERM CIC1436, UMR1214, and NS-Park/FCRIN Clinical Research Network Toulouse, Toulouse, France. · Pubmed 27430479
  • Institute of Cardiology Research, University of Buenos Aires, National Research Council (CONICET-ININCA), Buenos Aires, Argentina. · Department of Clinical Pharmacology and Neurosciences and NeuroToul Center of Excellence in Neurodegeneration (COEN), University Hospital and University of Toulouse III, Toulouse, France. · INSERM CIC1436 and UMR1214, Toulouse, France. · NS-Park/FCRIN Network, INSERM, Toulouse, France. · Pubmed 27344665
  • Service de Pharmacologie Médicale et Clinique, Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse, Toulouse, France. · Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament et Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · INSERM UMR 1027, Faculté de Médecine, Université de Toulouse, Toulouse, France. · CIC INSERM 1436, Université et Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire, France. · INSERM UMR 825, Université de Toulouse, Toulouse, France. · Département de Pharmacologie, Université et Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. · INSERM U 657, Pharmacoepidemiology, Université et Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. · Pubmed 27028036
  • a Institute of Cardiologic Research, National Scientific and Research Council (ININCA-CONICET), Faculty of Medicine , University of Buenos Aires , Buenos Aires , Argentina. · b Department of Clinical Pharmacology and Neurosciences , NeuroToul Excellence Center for Neurodegenerative Disorders, University Hospital and University of Toulouse 3 , Toulouse , France. · c INSERM CIC1436 and UMR825 , Toulouse , France. · d NS-Park Network, INSERM , Toulouse , France. · Pubmed 26849427
  • Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France. · CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France. · Service de Neurologie, CHU de Bordeaux, Bordeaux, France. · NS-Park/FCRIN Network, UMS 015, Toulouse, France. · Addex Pharma SA, Plan Les Ouates, Switzerland. · NS-Park/FCRIN Network, UMS 015, Toulouse, France. · Neurology Service, A, Hôpital Gabriel Montpied, Clermont Ferrand, France. · Sorbonne Universités and UPMC Univ Paris 06, INSERM UMRS-1127 and CIC-1422; CNRS UMR-7225; AP-HP; and ICM, Hôpital Pitié-Salpêtrière, Paris, France. · Universitätsklinikum Giessen und Marburg, Klinik für Neurologie, Marburg, Germany. · Department of Neurology USC/Keck School of Medicine, Los Angeles, California, USA. · Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, USA. · Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France. · CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France. · Rush University Medical Center, Dept. of Neurological Sciences, Movement Disorder Section, Chicago, Illinois, USA. · Paracelsus Elena Klinik, centre for Parkinson's Disease & Movement Disorders, Kassel, Germany. · CIC9302, Departments of Clinical Pharmacology and Neurosciences and NeuroToul COEN Center; INSERM, University Hospital of Toulouse and University of Toulouse 3, Toulouse, France. · Pubmed 27214664
  • INSERM, Imagerie Cérébrale et Handicaps Neurologiques, UMR 825, 31059, Toulouse, France. · Université de Toulouse (UPS), Imagerie Cérébrale et Handicaps Neurologiques, Toulouse, France. · Institute of Neurology, University Magna Graecia, Catanzaro, Italy. · Service of Neurology, University Hospital "Marqués de Valdecilla (IFIMAV)," University of Cantabria and "Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED),", Santander, Spain. · Neuroscience Department, Retzius vag 8, Karolinska Institutet, Stockholm, Sweden. · Centre de Référence Atrophie Multisystématisée, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · Centre de Référence Atrophie Multisystématisée, Centre Hospitalier Universitaire de Bordeaux, Pessac, France. · Service de Neurologie, Centre Hospitalier Universitaire de Bordeaux, Pessac, France. · Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France. · CNRS, Institut des Maladies Neurodégénératives, Bordeaux, France. · Département de Pharmacologie Clinique, INSERM CIC1436, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · Pubmed 26676922
2015
  • Department of Clinical Pharmacology and Neurosciences, University Hospital and University of Toulouse 3, France. · INSERM CIC1436 and UMR825, Toulouse, France. · Laboratory of Epidemiology and Experimental Pharmacology, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA). · National Scientific and Technological Research Council (CONICET), Buenos Aires, Argentina. · Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal. · Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal. · Pubmed 26293004
  • Department of Clinical Pharmacology and Neurosciences, University of Toulouse 3, 37 Allées Jules Guesde, 31000, Toulouse, France. · INSERM CIC1436 and UMR825, Toulouse, France. · NS-Park Network, INSERM, Toulouse, France. · Department of Clinical Pharmacology and Neurosciences, University of Toulouse 3, 37 Allées Jules Guesde, 31000, Toulouse, France. · Laboratory of Epidemiology and Experimental Pharmacology, Institute for Biomedical Research (BIOMED-CONICET), Faculty of Medical Sciences, Pontifical Catholic University of Argentina (UCA), Buenos Aires, Argentina. · NS-Park Network, INSERM, Toulouse, France. · Department of Neurology, Hôpital Laënnec, CHU Nantes, Nantes, France. · Department of Neurology, CHU Lille, Lille, France. · Department of Neurology, Hôpital Laënnec, CHU Nantes, Nantes, France. · NS-Park Network, INSERM, Toulouse, France. · Department of Neurology, CHU Lille, Lille, France. · INSERM U 837 Eq6, Lille, France. · Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, Bordeaux, France. · Institut des Maladies Neurodégénératives, UMR 5293, CNRS, Bordeaux, France. · Service de Neurologie, CHU de Bordeaux, Bordeaux, France. · NS-Park Network, INSERM, Toulouse, France. · Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, Bordeaux, France. · Institut des Maladies Neurodégénératives, UMR 5293, CNRS, Bordeaux, France. · Service de Neurologie, CHU de Bordeaux, Bordeaux, France. · NS-Park Network, INSERM, Toulouse, France. · LN Pharma, Toulouse, France. · Pubmed 25845678
2011
  • Department of Clinical Pharmacology, Faculty of Medicine, Toulouse, France. · Pubmed 21482191
2009
  • INSERM CIC-P302 and UMR-825, Department of Clinical Pharmacology, Faculté de Médecine, CHU and University UPS of Toulouse, Toulouse, France. · Pubmed 19877202
  • Clinical Investigation Center and Neurosciences Institute, Department of Clinical Pharmacology, Faculty of Medicine, INSERM U 825, Toulouse, France. · Pubmed 19239399
2012
  • Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, Toulouse, France. · Pubmed 23123689
  • INSERM, Imagerie cérébrale et handicaps neurologiques, Toulouse, France. · Pubmed 22964434
2011
  • Department of Clinical Pharmacology, Faculty of Medicine, Toulouse, France. · Pubmed 21453201
Show More
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here are the titles of the 10 most recent articles (out of 106 total) written by Olivier Rascol about Parkinson Disease:

  • Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease. 2017
  • Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. 2017
  • Mortality and Antipsychotic Drug Use in Elderly Patients With Parkinson Disease in Nursing Homes. 2017
  • Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease. 2017
  • Unmasking levodopa resistance in Parkinson's disease. 2016
  • Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. 2016
  • Atropinic (Anticholinergic) Burden in Parkinson's Disease. 2016
  • The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease. 2016
  • A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. 2016
  • A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. 2016
Show List of Full Article Records
Google Searches

Learn more about Olivier Rascol using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
Universite de Toulouse
IRCCS San Raffaele Pisana
Miscellaneous institutions in Toulouse
Affiliation Timeline
Click for institutional directory in table below. (Not always available.)
What is this?
Universite de Toulouse
2017
  • From the Institute of Neurology (F.S.), IRCCS San Raffaele, Rome, Italy; Departments of Clinical Pharmacology and Neurosciences (O.R.), Clinical Investigation Center CIC1436, NS-Park Clinical Research Network, NeuroToul Centre of Excellence in Neurodegeneration, INSERM, Toulouse University Hospital and Toulouse University, France; Parkinson's Disease and Movement Disorders Center (R.A.H.), USF Health-Byrd Institute, Tampa, FL; and Merck & Co., Inc. (S.H., A.T., R.C., T.W.H., P.S., C.L., D.M., D.J.H.), Kenilworth, NJ. · From the Institute of Neurology (F.S.), IRCCS San Raffaele, Rome, Italy; Departments of Clinical Pharmacology and Neurosciences (O.R.), Clinical Investigation Center CIC1436, NS-Park Clinical Research Network, NeuroToul Centre of Excellence in Neurodegeneration, INSERM, Toulouse University Hospital and Toulouse University, France; Parkinson's Disease and Movement Disorders Center (R.A.H.), USF Health-Byrd Institute, Tampa, FL; and Merck & Co., Inc. (S.H., A.T., R.C., T.W.H., P.S., C.L., D.M., D.J.H.), Kenilworth, NJ. · Pubmed 28490648
  • Reta Lila Weston Institute, University College London, London, England. · Centro de Estudos Egas Moniz, Hospital de Santa Maria, Lisbon, Portugal. · Department of Clinical Pharmacology, Institut National de la Santé et de la Recherche Medicale (INSERM) and University Hospital of Toulouse, Toulouse, France4Department of Neurosciences, INSERM and University Hospital of Toulouse, Toulouse, France. · Department of Neurology, Innsbruck Medical University, Innsbruck, Austria. · Department of Research and Development, BIAL-Portela & Ca SA, Sao Mamede do Coronado, Portugal. · Quintiles, Dublin, Ireland. · Department of Research and Development, BIAL-Portela & Ca SA, Sao Mamede do Coronado, Portugal8Department of Pharmacology and Therapeutics, University Porto, Porto, Portugal. · Pubmed 28027332
  • Laboratoire de Pharmacologie Médicale et Clinique, UMR Inserm 1027, CHU de Toulouse, France. · Pôle Pharmacie, UMR Inserm 1027, CHU de Toulouse, France. · Service de Gériatrie, CHU de Toulouse, UMR Inserm 1027, France. · Laboratoire de Pharmacologie Médicale et Clinique, CIC 1436, CHU de Toulouse, Inserm 1027, France. · Laboratoire de Pharmacologie Médicale et Clinique, CIC 1436, CHU de Toulouse, Inserm 1027, France. Electronic address: · Pubmed 28623157
  • Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · INSERM UMR 1027, Faculté de Médecine, Université de Toulouse, Toulouse, France. · CIC INSERM 1436, Université et Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire deToulouse, Toulouse, France. · INSERM UMR 825, Université de Toulouse, Toulouse, France. · Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · INSERM UMR 1027, Faculté de Médecine, Université de Toulouse, Toulouse, France. · CIC INSERM 1436, Université et Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire deToulouse, Toulouse, France. · Pubmed 27796464
2016
  • Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Rehabilitation, Nijmegen, The Netherlands. · Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands. · Department of Clinical Pharmacology and Neurosciences, NeuroToul Center of Excellence in Neurodegeneration (COEN), University Hospital and University of Toulouse, Toulouse, France. · INSERM CIC1436, UMR1214, and NS-Park/FCRIN Clinical Research Network Toulouse, Toulouse, France. · Pubmed 27430479
  • Institute of Cardiology Research, University of Buenos Aires, National Research Council (CONICET-ININCA), Buenos Aires, Argentina. · Department of Clinical Pharmacology and Neurosciences and NeuroToul Center of Excellence in Neurodegeneration (COEN), University Hospital and University of Toulouse III, Toulouse, France. · INSERM CIC1436 and UMR1214, Toulouse, France. · NS-Park/FCRIN Network, INSERM, Toulouse, France. · Pubmed 27344665
  • Service de Pharmacologie Médicale et Clinique, Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse, Toulouse, France. · Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament et Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · INSERM UMR 1027, Faculté de Médecine, Université de Toulouse, Toulouse, France. · CIC INSERM 1436, Université et Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire, France. · INSERM UMR 825, Université de Toulouse, Toulouse, France. · Département de Pharmacologie, Université et Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. · INSERM U 657, Pharmacoepidemiology, Université et Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. · Pubmed 27028036
  • a Institute of Cardiologic Research, National Scientific and Research Council (ININCA-CONICET), Faculty of Medicine , University of Buenos Aires , Buenos Aires , Argentina. · b Department of Clinical Pharmacology and Neurosciences , NeuroToul Excellence Center for Neurodegenerative Disorders, University Hospital and University of Toulouse 3 , Toulouse , France. · c INSERM CIC1436 and UMR825 , Toulouse , France. · d NS-Park Network, INSERM , Toulouse , France. · Pubmed 26849427
  • Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France. · CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France. · Service de Neurologie, CHU de Bordeaux, Bordeaux, France. · NS-Park/FCRIN Network, UMS 015, Toulouse, France. · Addex Pharma SA, Plan Les Ouates, Switzerland. · NS-Park/FCRIN Network, UMS 015, Toulouse, France. · Neurology Service, A, Hôpital Gabriel Montpied, Clermont Ferrand, France. · Sorbonne Universités and UPMC Univ Paris 06, INSERM UMRS-1127 and CIC-1422; CNRS UMR-7225; AP-HP; and ICM, Hôpital Pitié-Salpêtrière, Paris, France. · Universitätsklinikum Giessen und Marburg, Klinik für Neurologie, Marburg, Germany. · Department of Neurology USC/Keck School of Medicine, Los Angeles, California, USA. · Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, USA. · Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France. · CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France. · Rush University Medical Center, Dept. of Neurological Sciences, Movement Disorder Section, Chicago, Illinois, USA. · Paracelsus Elena Klinik, centre for Parkinson's Disease & Movement Disorders, Kassel, Germany. · CIC9302, Departments of Clinical Pharmacology and Neurosciences and NeuroToul COEN Center; INSERM, University Hospital of Toulouse and University of Toulouse 3, Toulouse, France. · Pubmed 27214664
  • Paracelsus-Elena Hospital, Kassel, Germany. · Department of Neurosurgery, University Medical Center, Goettingen, Germany. · German Parkinson Study Group, Marburg, Germany. · Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, Tübingen, Germany. · Department of Clinical Pharmacology and Neurosciences, NeuroToul Excellence Center for Neurodegenerative Disorders, University UPS of Toulouse III, CIC-9302/INSERM UMR825, Hôpital Purpan - Pavillon Riser, Toulouse, France. · NS PARK/FCRIN Network, France. · Department of Neurology, Philipps-University of Marburg, Marburg, Germany. · Schön Klinik München-Schwabing, München, Germany. · Sorbonne Universités, UPMC Univ Paris 06, and INSERM UMRS 1127 /CIC-1422, and CNRS UMR 7225, and AP-HP, and ICM, Hôpital Pitié-Salpêtrière, Département des maladies du système nerveux, Paris, France. · Division of Neurodegenerative Diseases, Department of Neurology, Dresden University of Technology, Dresden, Germany. · Department of Neurology, UC Davis MIND Institute, Sacramento, California, USA. · Service de Neurologie et pathologie du Mouvement, Hôpital de la Timone, Marseille Cedex, France. · Univisité Lyon 1, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Lyon, France. · CNRS UMR 5229, Centre de Neurosciences Cognitives, Team Basal Ganglia, Bron, France. · Service de Neurologie et Pathologie du movement, EA 1046, CHU de Lille, Hôpital Roger Salengro, Lille, France. · Movement to Health (M2H) laboratory, Euromov, University Montpellier 1, Hôpital gui de Chauliac, Montpellier, France. · Center for Neurological Restoration, Cleveland Clinic, Cleveland, Ohio, USA. · Department of Neurology, Institute for Research and Medical Care, IROCS, Rome, Italy. · Service de Neurologie, Hôpital de Hautepierre, Strasbourg, France. · Centre Investigation Clinique Neurologie, CHU Nantes, Hôpital G&R Laennec, Nantes, France. · Service de Neurologie, Hôpital Gabriel Montpied, Clermont-Ferrand, France. · Department of Neurology, James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, University of Cincinnati Academic Health Center, Cincinnati, Ohio, USA. · Feinstein Institute for Medical Research, North Shore - LIJ Health System, Manhasset, New York, USA. · Service de Neurologie, CIC-INSERM 1402, CHU de Poitiers, Université de Poitiers, Poitiers, France. · Klinik Haag, Haag, Germany. · Neuroscience Research Unit, Centre de recherche du CHU de Québec, Québec, Canada. · Faculty of Pharmacy, Laval University, Québec, Canada. · Novartis Institutes for BioMedical Research, Basel, Switzerland. · Biometrics Matters Ltd, Hamilton, New Zealand. · Albert Einstein College of Medicine, New York, NY, USA, and CognitionMetrics, LLC, Wilmington, Delaware, USA. · Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. · Inbiomed, San Sebastian, Spain. · CogState, Inc, New Haven, Connecticut, USA. · Department of Neurology and Neurosurgery, McGill University, Montreal, Québec, Canada. · Pubmed 26990766
  • Departments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC-1436, NS-Park/FCRIN Network and NeuroToul COEN Center of Excellence in Neurodegeneration, INSERM, University Hospital of Toulouse, and University of Toulouse 3, Toulouse, France. · Parkinson's Disease and Movement Disorders Center, NPF Center of Excellence, Tampa, Florida, USA. · Department of Neurology, Institute for Research and Medical Care IRCCS San Raffaele, Rome, Italy. · CHDI Management/CHDI Foundation, Princeton, New Jersey, USA. · Teva Pharmaceuticals, Petah Tikva, Israel. · Teva Pharmaceuticals, Frazer, Pennsylvania, USA. · Departments of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA. · Pubmed 27431201
  • Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal. · University College London, Reta Lila Weston Institute, London, UK. · Department of Research and Development, BIAL-Portela and Ca SA, S Mamede do Coronado, Portugal. · Department of Neurology, Innsbruck Medical University, Innsbruck, Austria. · Department of Clinical Pharmacology, INSERM and University Hospital of Toulouse, Toulouse France; Department of Neurosciences, INSERM and University Hospital of Toulouse, Toulouse France. · Department of Research and Development, BIAL-Portela and Ca SA, S Mamede do Coronado, Portugal; Department of Pharmacology and Therapeutics, Faculty of Medicine, University Porto, Porto, Portugal; MedInUP, Center for Drug Discovery and Innovative Medicines, University Porto, Porto, Portugal. Electronic address: · Pubmed 26725544
  • INSERM, Imagerie Cérébrale et Handicaps Neurologiques, UMR 825, 31059, Toulouse, France. · Université de Toulouse (UPS), Imagerie Cérébrale et Handicaps Neurologiques, Toulouse, France. · Institute of Neurology, University Magna Graecia, Catanzaro, Italy. · Service of Neurology, University Hospital "Marqués de Valdecilla (IFIMAV)," University of Cantabria and "Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED),", Santander, Spain. · Neuroscience Department, Retzius vag 8, Karolinska Institutet, Stockholm, Sweden. · Centre de Référence Atrophie Multisystématisée, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · Centre de Référence Atrophie Multisystématisée, Centre Hospitalier Universitaire de Bordeaux, Pessac, France. · Service de Neurologie, Centre Hospitalier Universitaire de Bordeaux, Pessac, France. · Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France. · CNRS, Institut des Maladies Neurodégénératives, Bordeaux, France. · Département de Pharmacologie Clinique, INSERM CIC1436, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · Pubmed 26676922
  • Clinical Investigation Center CIC1436 and Department of Clinical Pharmacology and Neurosciences, INSERM, Toulouse University Hospital and University of Toulouse, Toulouse, France. · University of South Florida Ataxia Research Center, The Frances J. Zesiewicz Foundation for Parkinson's Disease at USF, Parkinson's Disease and Movement Disorders Clinic at the PADREC, James A. Haley Veterans' Administration, Tampa, FL, USA. · National Parkinson's Foundation International Centre of Excellence, King's College Hospital, Kings College and Kings Health Partners, London, UK. · UCB Pharma, Raleigh, NC, USA. · UCB Pharma, Monheim am Rhein, Germany. · UCB Pharma, Brussels, Belgium. · Pubmed 26626320
2015
  • Department of Clinical Pharmacology and Neurosciences, University Hospital and University of Toulouse 3, France. · INSERM CIC1436 and UMR825, Toulouse, France. · Laboratory of Epidemiology and Experimental Pharmacology, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA). · National Scientific and Technological Research Council (CONICET), Buenos Aires, Argentina. · Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal. · Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal. · Pubmed 26293004
  • Parkinson's Disease and Movement Disorders Center, University of South Florida, National Parkinson Foundation Center of Excellence, Tampa. · Institute of Neurology, L'Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele, Rome, Italy. · Clinical Investigation Center, Institut National de la Santé et de la Récherche Médicale, Toulouse University, Toulouse, France. · Merck & Co, Inc, Kenilworth, New Jersey. · Pubmed 26523919
  • Paracelsus-Elena Hospital, Kassel, Germany; Department of Neurosurgery, University Medical Centre, Goettingen, Germany. Electronic address: · National Parkinson's Foundation, Parkinson's Centre of Excellence, King's College Hospital, London, UK; Biomedical Research Unit for Dementia, King's College, London, UK. · National Centre of Epidemiology, Carlos III Institute of Health, Madrid, Spain. · Clinical Investigation Centre 1436, INSERM, Toulouse, France; University Hospital, Toulouse, France. · Neurologie Berlin, Gemeinschaftspraxis, Berlin, Germany. · Poliklinika Chocen Neuro, Chocen, Czech Republic; Department of Neurology, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Hradec Králové, Czech Republic. · Department of Neurology, Vaszary Kolos Hospital, Esztergom, Hungary. · Department of Neurology, Jagiellonian University, Krakow, Poland. · Parkinson's Disease and Movement Disorders Unit, Department of Neurology, Hospital Clinic, CIBERNED, Barcelona, Spain. · Mundipharma Research, Limburg an der Lahn, Germany; Private University Witten/Herdecke, Faculty of Health, Witten, Germany. · Mundipharma Research, Limburg an der Lahn, Germany; Rudolf-Buchheim Institute of Pharmacology, Justus-Liebig-Universität Giessen, Germany. · Mundipharma Research, Cambridge, UK. · Mundipharma Research, Limburg an der Lahn, Germany. · Pubmed 26494524
  • Wolfson Centre for Age-Related Diseases, King's College London, London, UK. Electronic address: · Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL. · ACADIA Pharmaceuticals, San Diego, CA. · Wolfson Centre for Age-Related Diseases, King's College London, London, UK. · University of Kansas Medical Center, Kansas City, KS. · Department of Clinical Pharmacology and Neurosciences, University UPS of Toulouse III, Toulouse, France. · Institute of Neuroscience, Newcastle University, Newcastle, UK. · Pubmed 26239690
  • Department of Clinical Pharmacology, Paul Sabatier University and Toulouse University Hospital, Toulouse, France; INSERM UMR825 Neuroimaging and Neurologic Diseases, Toulouse, France; Sleep and Epilepsy Center, Neurocenter of Southern Switzerland, Civic Hospital (EOC) of Lugano, Switzerland. Electronic address: · Department of Clinical Pharmacology, Paul Sabatier University and Toulouse University Hospital, Toulouse, France; LN-Pharma, Toulouse, France. · Department of Clinical Pharmacology, Paul Sabatier University and Toulouse University Hospital, Toulouse, France. · Sleep Medicine and Epilepsy Unit, IRCCS "C. Mondino National Institute of Neurology" Foundation, Pavia, Italy. · Pôle Neurosciences, Centre Hospitalier Universitaire de Nantes, Centre d'Investigation Clinique CIC 04, Nantes, France. · Service de Neurologie, Groupe Hospitalier Sud, Hôpital Haut-Lévèque, Centre Hospitalier Universitaire de Bordeaux, France. · Service de Neurologie et pathologie du mouvement, Pôle de Neurologie, Centre Hospitalier Universitaire de Lille, France. · Department of Clinical Pharmacology, Paul Sabatier University and Toulouse University Hospital, Toulouse, France; INSERM UMR825 Neuroimaging and Neurologic Diseases, Toulouse, France; Centre d'Investigation Clinique CIC 9302, Toulouse University Hospital, Toulouse, France. · Pubmed 26411501
  • Department of Clinical Pharmacology and Neurosciences, University of Toulouse 3, 37 Allées Jules Guesde, 31000, Toulouse, France. · INSERM CIC1436 and UMR825, Toulouse, France. · NS-Park Network, INSERM, Toulouse, France. · Department of Clinical Pharmacology and Neurosciences, University of Toulouse 3, 37 Allées Jules Guesde, 31000, Toulouse, France. · Laboratory of Epidemiology and Experimental Pharmacology, Institute for Biomedical Research (BIOMED-CONICET), Faculty of Medical Sciences, Pontifical Catholic University of Argentina (UCA), Buenos Aires, Argentina. · NS-Park Network, INSERM, Toulouse, France. · Department of Neurology, Hôpital Laënnec, CHU Nantes, Nantes, France. · Department of Neurology, CHU Lille, Lille, France. · Department of Neurology, Hôpital Laënnec, CHU Nantes, Nantes, France. · NS-Park Network, INSERM, Toulouse, France. · Department of Neurology, CHU Lille, Lille, France. · INSERM U 837 Eq6, Lille, France. · Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, Bordeaux, France. · Institut des Maladies Neurodégénératives, UMR 5293, CNRS, Bordeaux, France. · Service de Neurologie, CHU de Bordeaux, Bordeaux, France. · NS-Park Network, INSERM, Toulouse, France. · Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, Bordeaux, France. · Institut des Maladies Neurodégénératives, UMR 5293, CNRS, Bordeaux, France. · Service de Neurologie, CHU de Bordeaux, Bordeaux, France. · NS-Park Network, INSERM, Toulouse, France. · LN Pharma, Toulouse, France. · Pubmed 25845678
  • 1 Department of Movement Disorders and Neurology, Lille University, CHU Lille, Lille, France 2 INSERM U1171, Lille University, Lille, France. · 3 Department of Molecular Biology and Pathology Centre, Lille University, CHU Lille, Lille, France. · 4 Sorbonne Universités, UPMC Univ Paris 06, and INSERM UMRS_1127 and CIC_1422, and CNRS UMR_7225, and AP-HP, and ICM, Hôpital Pitié-Salpêtrière, Département des Maladies du Système Nerveux, Paris, France. · 5 Department of Biostatistics, Lille University, CHU Lille, Lille, France. · 2 INSERM U1171, Lille University, Lille, France. · 6 Department of Nuclear Medicine, Lille University, CHU Lille, Lille, France. · 7 Departments of Clinical Pharmacology and Neurosciences, CIC9302, University Hospital and Paul Sabatier University, Toulouse, France. · 8 Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR CNRS 5293 and CHU de Bordeaux, Bordeaux, France. · 9 Department of Neurology and Movement Disorders - APHM Timone University Hospital and Institut de Neurosciences de la Timone, AMU-CNRS UMR 7289, Marseille, France. · 10 Department of Psychiatry and Neurology, CHU Grenoble, Grenoble, France. · 11 Department of Movement Disorders and Neurology, Centre d'Investigation Clinique, INSERM CIC 0802, INSERM U1084, Laboratoire de Neurosciences Expérimentales et Cliniques, CHU de Poitiers, Poitiers, France. · 12 Department of Movement Disorders and Neurology, CHU Strasbourg, Strasbourg, France. · 13 Department of Movement Disorders and Neurology, CHU Clermont-Ferrand, Clermont-Ferrand, France. · 14 Department of Movement Disorders and Neurology, INSERM, CIC04, CHU Nantes, Nantes, France. · 15 Department of Movement Disorders and Neurology, CHU Nice, Nice, France. · 16 Department of Neurology, EA- 425 Université Rennes 1 et CHU Pontchaillou, CHU Rennes, Rennes, France. · 17 Department of Neurology and INSERM CIC-CRB 0204, Rouen University Hospital, CHU Rouen Rouen, France. · 1 Department of Movement Disorders and Neurology, Lille University, CHU Lille, Lille, France 18 INSERM U837/6 Lille JPARC, France. · 7 Departments of Clinical Pharmacology and Neurosciences, CIC9302, University Hospital and Paul Sabatier University, Toulouse, France 19 INSERM NS-PARK National Network, France. · 2 INSERM U1171, Lille University, Lille, France 18 INSERM U837/6 Lille JPARC, France. · 1 Department of Movement Disorders and Neurology, Lille University, CHU Lille, Lille, France 2 INSERM U1171, Lille University, Lille, France 20 Department of Medical Pharmacology, Lille University, CHU Lille, Lille, France · Pubmed 25805645
  • Department of Clinical Pharmacology, Toulouse University Hospital and Paul Sabatier University, Toulouse, France; UMR 825 Brain imaging and neurological dysfunctions, INSERM, Toulouse, France; Sleep and Epilepsy center, Neurocenter of Southern Switzerland, Civic Hospital (EOC) of Lugano, Lugano, Switzerland. · Department of Neurology, Toulouse University Hospital and Paul Sabatier University, Toulouse, France. · Sleep Medicine and Epilepsy unit, C. Mondino National Neurological Institute, Pavia, Italy. · UMR 825 Brain imaging and neurological dysfunctions, INSERM, Toulouse, France; Department of Neurology, Toulouse University Hospital and Paul Sabatier University, Toulouse, France. · Brain Function & Neuromodulation, Grenoble Institute of Neuroscience, Grenoble, France; Joseph Fourier University, Grenoble, France. · Brain Function & Neuromodulation, Grenoble Institute of Neuroscience, Grenoble, France. · Department of Clinical Pharmacology, Toulouse University Hospital and Paul Sabatier University, Toulouse, France; UMR 825 Brain imaging and neurological dysfunctions, INSERM, Toulouse, France; Reference Centre for Multiple System Atrophy, Toulouse University Hospital, Toulouse, France. · Pubmed 25756280
  • INSERM, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU PURPAN, Toulouse, France; Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU PURPAN, Toulouse, France. Electronic address: · Radiology Department, Santa Lucia Foundation, Rome, Italy. · INSERM, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU PURPAN, Toulouse, France; Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU PURPAN, Toulouse, France; Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, CHU PURPAN, Toulouse, France; Service de Pharmacologie Clinique, Faculté de Médecine, Toulouse, France; Inserm, Centre d'Investigation Clinique 9302, CHU Purpan, Toulouse, France. · INSERM, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU PURPAN, Toulouse, France; Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU PURPAN, Toulouse, France. · Pubmed 25174648
2014
  • Clinical Investigation Center CIC9302 and Department of Neurosciences and Clinical Pharmacology, INSERM UMR825, Toulouse University Hospital and University of Toulouse III, Toulouse, France. · Movement Disorder Clinic, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada. · Novartis Institutes for Biomedical Research, Basel, Switzerland. · Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. · Neuroscience Research Unit, Centre Hospitalier Universitaire de Québec, Québec, Canada; Faculty of Pharmacy, Laval University, Québec, Canada. · Novartis Institutes for Biomedical Research, Basel, Switzerland; Department of Neurology and Neurosurgery, McGill University, Montreal, Québec, Canada. Electronic address: · Pubmed 24951359
  • Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France. · CHU de Bordeaux, Unité de Soutien Méthodologique à la Recherche Clinique (USMR), Pôle de santé publique, Bordeaux, France. · Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France; Service de Neurologie, CHU de Bordeaux, F-33604 Pessac, France. · Centre de référence atrophie multisystématisée, CHU de Toulouse, Toulouse, France. · Centre de référence atrophie multisystématisée, CHU de Toulouse, Toulouse, France; Department of Clinical Pharmacology, University Hospital and University of Toulouse 3, Toulouse, France; Department of Neurosciences, University Hospital and University of Toulouse 3, Toulouse, France; INSERM UMR825 and CIC9302, Toulouse, France. · Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France; Service de Neurologie, CHU de Bordeaux, F-33604 Pessac, France; Centre de référence atrophie multisystématisée, CHU de Bordeaux, Pessac, France. · Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France; Service de Neurologie, CHU de Bordeaux, F-33604 Pessac, France; Centre de référence atrophie multisystématisée, CHU de Bordeaux, Pessac, France. Electronic address: · Pubmed 24727096
  • AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesthésie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Créteil, France; Université Paris 12, Faculté de Médecine, Créteil, France. Electronic address: · AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesthésie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Créteil, France; Université Paris 12, Faculté de Médecine, Créteil, France. · Oxford BioMedica, Oxford, UK. · CEA, DSV I(2)BM, MIRCen and CNRS URA2210, Fontenay-aux-Roses, France. · John van Geest Centre for Brain Repair and Addenbrooke's Hospital, Cambridge, UK. · AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesthésie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Créteil, France; Université Paris 12, Faculté de Médecine, Créteil, France; INSERM U955, E01, Institut de Recherche Biomédicale, Créteil, France. · Gene Therapy, Centre of Neuroinflammation and Neurodegeneration, Division of Brain Sciences, Faculty of Medicine, Hammersmith Hospital Campus, London, UK. · CIC9302 and UMR 825, INSERM and Department of Pharmacology and Neurosciences, University Hospital and University of Toulouse III, Toulouse, France. · AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesthésie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Créteil, France; Université Paris 12, Faculté de Médecine, Créteil, France; CEA, DSV I(2)BM, MIRCen and CNRS URA2210, Fontenay-aux-Roses, France. · Pubmed 24412048
  • Clinical Investigation Centre CIC1436, Departments of Clinical Pharmacology and Neurosciences, INSERM and Toulouse University Hospital, University of Toulouse 3, Place du Docteur Baylac, TSA 40031, 31059 Toulouse CEDEX 9, France. · Pubmed 25134709
  • Department of Clinical Pharmacology, Faculty of Medicine, University Hospital, University of Toulouse, Toulouse, France2Department of Neurosciences, University Hospital, University of Toulouse, Toulouse, France3Clinical Investigation Center 1436, Universi. · LN Pharma, Toulouse, France. · Department of Neurology, Hôpital Laënnec, Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France6NS-Park Network, INSERM, Toulouse, France. · Department of Neurology, CHU Lille, Lille, France. · NS-Park Network, INSERM, Toulouse, France7Department of Neurology, CHU Lille, Lille, France8INSERM U 837 Eq6, Lille, France. · Institut des Maladies Neurodégénératives, Université de Bordeaux, Bordeaux, France10Centre National de la Recherche Scientifique, Institut des Maladies Neurodégénératives, Bordeaux, France11Service de Neurologie, CHU de Bordeaux, Bordeaux, France. · Neurology Department, Kantonsspital Münsterlingen, Münsterlingen, Switzerland. · NS-Park Network, INSERM, Toulouse, France9Institut des Maladies Neurodégénératives, Université de Bordeaux, Bordeaux, France10Centre National de la Recherche Scientifique, Institut des Maladies Neurodégénératives, Bordeaux, France11Service de Neurologie. · Pubmed 24839938
  • Clinical Investigation Center CIC-9302, NS-Park Network and Departments of Clinical Pharmacology and Neurosciences, INSERM, Toulouse University Hospital and University Paul Sabatier Toulouse III, Toulouse, France. Electronic address: · Pubmed 24361113
2013
  • CIC-9302/INSERM UMR825, Departments of Clinical Pharmacology and Neurosciences, University UPS of Toulouse III, Toulouse, France. · Pubmed 23485609
2012
  • Institut National de la Santé et de la Recherche Médicale Clinical Investigation Center, Toulouse University Hospital and University of Toulouse, France. · Pubmed 22222634
  • Department of Clinical Pharmacology, Hospital and University Paul Sabatier of Toulouse, France. · Pubmed 21585523
2011
  • Department of Clinical Pharmacology, University Hospital of Toulouse, France. · Pubmed 21626552
2010
  • Departments of Clinical Pharmacology and Neurosciences, Toulouse University Hospital, INSERM CIC9302-UMR825 Toulouse, France. · Pubmed 20669265
  • Department of Clinical Pharmacology, INSERM Clinical Investigation Center CIC-9302 and UMR-825, CHU Toulouse-Purpan and University Paul Sabatier, Toulouse, France. · Pubmed 20063435
2009
  • Clinical Investigation Center, Department of Neurosciences, University Hospital of Toulouse, INSERM UMR 825, Toulouse, France. · Pubmed 19221315
2008
  • Laboratoire de Pharmacologie Médicale et Clinique, Pôle Neurosciences, Centre d'Investigations Cliniques, Institut National de la Santé et de la Récherche Médicale, Unité 825, University Hospital, Toulouse, France. · Pubmed 18474731
2014
  • Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences , Toulouse , France. · Pubmed 24547918
  • Departments of Clinical Pharmacology and Neurosciences, Faculty of Medicine, University Hospital and University of Toulouse 3, 37 Allées Jules Guesde, 31000, Toulouse, France, · Pubmed 24683045
  • From INSERM, Clinical Investigation Center 9302 (F.O.-M., C.B.-C., E.D., M.G., C.T., A.S., O.R.), and Department of Neurology (F.O.-M., C.B.-C., O.R.), University Hospital of Toulouse; INSERM, Clinical Investigation Center 9503 (J.-C.C., A.-M.B., M.V.), and AP-HP, Department of Neurology (J.-C.C., A.-M.B., M.V.), Pitié-Salpêtrière Hospital, Paris; CRICM UPMC/INSERM UMR_S975 CNRS UMR7225 (J.-C.C., M.V.), Institut de la Moelle et du Cerveau, Université Pierre Marie Curie Paris-6, Salpêtrière, Paris; AP-HM (J.-P.A.), Department of Neurology, Timone Hospital, Marseille; Department of Clinical Pharmacology (C.B.-C., C.T., A.S., O.R.), University of Medicine, Toulouse; INSERM (C.B.-C., O.R.), and Université de Toulouse, UPS (C.B.-C., O.R.), Imagerie cérébrale et handicaps neurologiques, UMR 825, Toulouse; Department of Neurology (P.D., T.L.), University Hospital of Nantes; Department of Neurology (A.D.), University Hospital of Lille; Department of Neurology (F.D.), University Hospital of Clermont-Ferrand; Department of Neurology (W.M., F.T.), University Hospital of Bordeaux; and Department of Neurology (F.V.), Pays-d'Aix Hospital, Aix-en-Provence, France. · Pubmed 24371304
2013
  • University of Toulouse III, University Hospital, Department of Clinical Pharmacology and Neuroscience, Toulouse, France. · Pubmed 23373820
  • Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse, Toulouse, France. · Pubmed 22320451
  • Inserm, Imagerie cérébrale et handicaps neurologiques, UMR 825, F-31059 Toulouse, France - Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, F-31059 Toulouse, France. · Pubmed 23462484
2012
  • University Hospital and University Paul Sabatier Toulouse 3, Departments of Clinical Pharmacology and Neurosciences, France. · Pubmed 22530847
  • Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, l'Université de Toulouse, Toulouse, France. · Pubmed 22336566
  • Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, Faculté de Médecine, Université de Toulouse, Toulouse, France. · Pubmed 22205275
2011
  • Departments of Clinical Pharmacology and Neurosciences, University Hospital and University of Toulouse, France and INSERM CIC-9023 and UMR-825, Toulouse, France; Department of Clinical Pharmacology, Faculty of Medicine, 37 Allées Jules Guesde, 31000, Toulouse, France. · Pubmed 21721909
  • Reference Centre for MSA, University Hospital, INSERM U1048 Eq8, Toulouse, France. · Pubmed 21547951
2010
  • Department of Clinical Pharmacology and Neurosciences, Hospital and University of Toulouse and INSERM CIC9023 and UMR 825, Toulouse, France. · Pubmed 20932066
  • Department of Clinical Pharmacology, University of Toulouse, Faculty of Medicine, 37 Allées Jules Guesde, 31000 Toulouse, France. · Pubmed 20670197
  • Department of Neurosciences, University Hospital, Toulouse, France. · Pubmed 20803301
2009
2008
  • Department of Clinical Pharmacology, University Hospital, Toulouse, France. · Pubmed 18546344
2007
  • Department of Neurology, University Hospital CHU, Toulouse, France. · Pubmed 17516457
IRCCS San Raffaele Pisana
2017
  • From the Institute of Neurology (F.S.), IRCCS San Raffaele, Rome, Italy; Departments of Clinical Pharmacology and Neurosciences (O.R.), Clinical Investigation Center CIC1436, NS-Park Clinical Research Network, NeuroToul Centre of Excellence in Neurodegeneration, INSERM, Toulouse University Hospital and Toulouse University, France; Parkinson's Disease and Movement Disorders Center (R.A.H.), USF Health-Byrd Institute, Tampa, FL; and Merck & Co., Inc. (S.H., A.T., R.C., T.W.H., P.S., C.L., D.M., D.J.H.), Kenilworth, NJ. · From the Institute of Neurology (F.S.), IRCCS San Raffaele, Rome, Italy; Departments of Clinical Pharmacology and Neurosciences (O.R.), Clinical Investigation Center CIC1436, NS-Park Clinical Research Network, NeuroToul Centre of Excellence in Neurodegeneration, INSERM, Toulouse University Hospital and Toulouse University, France; Parkinson's Disease and Movement Disorders Center (R.A.H.), USF Health-Byrd Institute, Tampa, FL; and Merck & Co., Inc. (S.H., A.T., R.C., T.W.H., P.S., C.L., D.M., D.J.H.), Kenilworth, NJ. · Pubmed 28490648
2013
  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy. · Pubmed 23853029
2010
  • Institute of Neurology, IRCCS San Raffaele Pisana, Rome, Italy. · Pubmed 20582993
Miscellaneous institutions in Toulouse
2017
  • Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · INSERM UMR 1027, Faculté de Médecine, Université de Toulouse, Toulouse, France. · CIC INSERM 1436, Université et Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire deToulouse, Toulouse, France. · INSERM UMR 825, Université de Toulouse, Toulouse, France. · Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · INSERM UMR 1027, Faculté de Médecine, Université de Toulouse, Toulouse, France. · CIC INSERM 1436, Université et Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire deToulouse, Toulouse, France. · Pubmed 27796464
2016
  • Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Rehabilitation, Nijmegen, The Netherlands. · Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands. · Department of Clinical Pharmacology and Neurosciences, NeuroToul Center of Excellence in Neurodegeneration (COEN), University Hospital and University of Toulouse, Toulouse, France. · INSERM CIC1436, UMR1214, and NS-Park/FCRIN Clinical Research Network Toulouse, Toulouse, France. · Pubmed 27430479
  • Institute of Cardiology Research, University of Buenos Aires, National Research Council (CONICET-ININCA), Buenos Aires, Argentina. · Department of Clinical Pharmacology and Neurosciences and NeuroToul Center of Excellence in Neurodegeneration (COEN), University Hospital and University of Toulouse III, Toulouse, France. · INSERM CIC1436 and UMR1214, Toulouse, France. · NS-Park/FCRIN Network, INSERM, Toulouse, France. · Pubmed 27344665
  • Service de Pharmacologie Médicale et Clinique, Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse, Toulouse, France. · Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament et Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · INSERM UMR 1027, Faculté de Médecine, Université de Toulouse, Toulouse, France. · CIC INSERM 1436, Université et Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire, France. · INSERM UMR 825, Université de Toulouse, Toulouse, France. · Département de Pharmacologie, Université et Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. · INSERM U 657, Pharmacoepidemiology, Université et Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. · Pubmed 27028036
  • a Institute of Cardiologic Research, National Scientific and Research Council (ININCA-CONICET), Faculty of Medicine , University of Buenos Aires , Buenos Aires , Argentina. · b Department of Clinical Pharmacology and Neurosciences , NeuroToul Excellence Center for Neurodegenerative Disorders, University Hospital and University of Toulouse 3 , Toulouse , France. · c INSERM CIC1436 and UMR825 , Toulouse , France. · d NS-Park Network, INSERM , Toulouse , France. · Pubmed 26849427
  • Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France. · CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France. · Service de Neurologie, CHU de Bordeaux, Bordeaux, France. · NS-Park/FCRIN Network, UMS 015, Toulouse, France. · Addex Pharma SA, Plan Les Ouates, Switzerland. · NS-Park/FCRIN Network, UMS 015, Toulouse, France. · Neurology Service, A, Hôpital Gabriel Montpied, Clermont Ferrand, France. · Sorbonne Universités and UPMC Univ Paris 06, INSERM UMRS-1127 and CIC-1422; CNRS UMR-7225; AP-HP; and ICM, Hôpital Pitié-Salpêtrière, Paris, France. · Universitätsklinikum Giessen und Marburg, Klinik für Neurologie, Marburg, Germany. · Department of Neurology USC/Keck School of Medicine, Los Angeles, California, USA. · Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, USA. · Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France. · CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France. · Rush University Medical Center, Dept. of Neurological Sciences, Movement Disorder Section, Chicago, Illinois, USA. · Paracelsus Elena Klinik, centre for Parkinson's Disease & Movement Disorders, Kassel, Germany. · CIC9302, Departments of Clinical Pharmacology and Neurosciences and NeuroToul COEN Center; INSERM, University Hospital of Toulouse and University of Toulouse 3, Toulouse, France. · Pubmed 27214664
  • INSERM, Imagerie Cérébrale et Handicaps Neurologiques, UMR 825, 31059, Toulouse, France. · Université de Toulouse (UPS), Imagerie Cérébrale et Handicaps Neurologiques, Toulouse, France. · Institute of Neurology, University Magna Graecia, Catanzaro, Italy. · Service of Neurology, University Hospital "Marqués de Valdecilla (IFIMAV)," University of Cantabria and "Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED),", Santander, Spain. · Neuroscience Department, Retzius vag 8, Karolinska Institutet, Stockholm, Sweden. · Centre de Référence Atrophie Multisystématisée, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · Centre de Référence Atrophie Multisystématisée, Centre Hospitalier Universitaire de Bordeaux, Pessac, France. · Service de Neurologie, Centre Hospitalier Universitaire de Bordeaux, Pessac, France. · Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France. · CNRS, Institut des Maladies Neurodégénératives, Bordeaux, France. · Département de Pharmacologie Clinique, INSERM CIC1436, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · Pubmed 26676922
2015
  • Department of Clinical Pharmacology and Neurosciences, University Hospital and University of Toulouse 3, France. · INSERM CIC1436 and UMR825, Toulouse, France. · Laboratory of Epidemiology and Experimental Pharmacology, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA). · National Scientific and Technological Research Council (CONICET), Buenos Aires, Argentina. · Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal. · Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal. · Pubmed 26293004
  • Department of Clinical Pharmacology and Neurosciences, University of Toulouse 3, 37 Allées Jules Guesde, 31000, Toulouse, France. · INSERM CIC1436 and UMR825, Toulouse, France. · NS-Park Network, INSERM, Toulouse, France. · Department of Clinical Pharmacology and Neurosciences, University of Toulouse 3, 37 Allées Jules Guesde, 31000, Toulouse, France. · Laboratory of Epidemiology and Experimental Pharmacology, Institute for Biomedical Research (BIOMED-CONICET), Faculty of Medical Sciences, Pontifical Catholic University of Argentina (UCA), Buenos Aires, Argentina. · NS-Park Network, INSERM, Toulouse, France. · Department of Neurology, Hôpital Laënnec, CHU Nantes, Nantes, France. · Department of Neurology, CHU Lille, Lille, France. · Department of Neurology, Hôpital Laënnec, CHU Nantes, Nantes, France. · NS-Park Network, INSERM, Toulouse, France. · Department of Neurology, CHU Lille, Lille, France. · INSERM U 837 Eq6, Lille, France. · Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, Bordeaux, France. · Institut des Maladies Neurodégénératives, UMR 5293, CNRS, Bordeaux, France. · Service de Neurologie, CHU de Bordeaux, Bordeaux, France. · NS-Park Network, INSERM, Toulouse, France. · Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, Bordeaux, France. · Institut des Maladies Neurodégénératives, UMR 5293, CNRS, Bordeaux, France. · Service de Neurologie, CHU de Bordeaux, Bordeaux, France. · NS-Park Network, INSERM, Toulouse, France. · LN Pharma, Toulouse, France. · Pubmed 25845678
2011
  • Department of Clinical Pharmacology, Faculty of Medicine, Toulouse, France. · Pubmed 21482191
2009
  • INSERM CIC-P302 and UMR-825, Department of Clinical Pharmacology, Faculté de Médecine, CHU and University UPS of Toulouse, Toulouse, France. · Pubmed 19877202
  • Clinical Investigation Center and Neurosciences Institute, Department of Clinical Pharmacology, Faculty of Medicine, INSERM U 825, Toulouse, France. · Pubmed 19239399
2012
  • Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, Toulouse, France. · Pubmed 23123689
  • INSERM, Imagerie cérébrale et handicaps neurologiques, Toulouse, France. · Pubmed 22964434
2011
  • Department of Clinical Pharmacology, Faculty of Medicine, Toulouse, France. · Pubmed 21453201
Miscellaneous cities in France
2016
  • Service de Pharmacologie Médicale et Clinique, Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse, Toulouse, France. · Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament et Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · INSERM UMR 1027, Faculté de Médecine, Université de Toulouse, Toulouse, France. · CIC INSERM 1436, Université et Centre Hospitalier Universitaire de Toulouse, Toulouse, France. · NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire, France. · INSERM UMR 825, Université de Toulouse, Toulouse, France. · Département de Pharmacologie, Université et Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. · INSERM U 657, Pharmacoepidemiology, Université et Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. · Pubmed 27028036
  • Paracelsus-Elena Hospital, Kassel, Germany. · Department of Neurosurgery, University Medical Center, Goettingen, Germany. · German Parkinson Study Group, Marburg, Germany. · Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, Tübingen, Germany. · Department of Clinical Pharmacology and Neurosciences, NeuroToul Excellence Center for Neurodegenerative Disorders, University UPS of Toulouse III, CIC-9302/INSERM UMR825, Hôpital Purpan - Pavillon Riser, Toulouse, France. · NS PARK/FCRIN Network, France. · Department of Neurology, Philipps-University of Marburg, Marburg, Germany. · Schön Klinik München-Schwabing, München, Germany. · Sorbonne Universités, UPMC Univ Paris 06, and INSERM UMRS 1127 /CIC-1422, and CNRS UMR 7225, and AP-HP, and ICM, Hôpital Pitié-Salpêtrière, Département des maladies du système nerveux, Paris, France. · Division of Neurodegenerative Diseases, Department of Neurology, Dresden University of Technology, Dresden, Germany. · Department of Neurology, UC Davis MIND Institute, Sacramento, California, USA. · Service de Neurologie et pathologie du Mouvement, Hôpital de la Timone, Marseille Cedex, France. · Univisité Lyon 1, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Lyon, France. · CNRS UMR 5229, Centre de Neurosciences Cognitives, Team Basal Ganglia, Bron, France. · Service de Neurologie et Pathologie du movement, EA 1046, CHU de Lille, Hôpital Roger Salengro, Lille, France. · Movement to Health (M2H) laboratory, Euromov, University Montpellier 1, Hôpital gui de Chauliac, Montpellier, France. · Center for Neurological Restoration, Cleveland Clinic, Cleveland, Ohio, USA. · Department of Neurology, Institute for Research and Medical Care, IROCS, Rome, Italy. · Service de Neurologie, Hôpital de Hautepierre, Strasbourg, France. · Centre Investigation Clinique Neurologie, CHU Nantes, Hôpital G&R Laennec, Nantes, France. · Service de Neurologie, Hôpital Gabriel Montpied, Clermont-Ferrand, France. · Department of Neurology, James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, University of Cincinnati Academic Health Center, Cincinnati, Ohio, USA. · Feinstein Institute for Medical Research, North Shore - LIJ Health System, Manhasset, New York, USA. · Service de Neurologie, CIC-INSERM 1402, CHU de Poitiers, Université de Poitiers, Poitiers, France. · Klinik Haag, Haag, Germany. · Neuroscience Research Unit, Centre de recherche du CHU de Québec, Québec, Canada. · Faculty of Pharmacy, Laval University, Québec, Canada. · Novartis Institutes for BioMedical Research, Basel, Switzerland. · Biometrics Matters Ltd, Hamilton, New Zealand. · Albert Einstein College of Medicine, New York, NY, USA, and CognitionMetrics, LLC, Wilmington, Delaware, USA. · Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. · Inbiomed, San Sebastian, Spain. · CogState, Inc, New Haven, Connecticut, USA. · Department of Neurology and Neurosurgery, McGill University, Montreal, Québec, Canada. · Pubmed 26990766
2010
  • Department of Clinical Pharmacology and Neurosciences, INSERM U825, and Clinical Investigation Center, University Hospital, France. · Pubmed 21921459
27 Other Locations Show
Yearly article counts 04119914111017966
 
Remember this Person You can save this page -- like a bookmark -- so it's remembered for you on the Expertscape "Saved Pages" page, which is always easily available from the page-top menu bar throughout the site.